Citius Pharmaceuticals and Citius Oncology Announce Unique Permanent J-Code Issued for LYMPHIR by Centers for Medicare and Medicaid Services
- Permanent J-Code (J9161) expected to be effective April 1, 2025 LYMPHIR is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy. CRANFORD, N.J.
- 02/06/2025
|
Citius Pharmaceuticals Announces $3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
- CRANFORD, N.J. , Jan. 8, 2025 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius Pharma" or the "Company"), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that it has entered into definitive agreements for the purchase of an aggregate of 743,496 shares of its common stock and accompanying warrants to purchase up to an aggregate of 743,496 shares of its common stock, at a purchase price of $4.035 per share and accompanying warrant in a registered direct offering priced at-the-market under Nasdaq rules.
- 01/08/2025
|
Citius Pharmaceuticals and Citius Oncology Highlight LYMPHIR Commercial Launch Planned for the First Half of 2025
- CRANFORD, N.J. , Jan. 7, 2025 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR) and its oncology-focused subsidiary, Citius Oncology (Nasdaq: CTOR), today announced significant progress in preparations for the commercial launch of LYMPHIR™, an innovative immunotherapy for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma (CTCL).
- 01/07/2025
|
Citius Oncology Engages Jefferies as Exclusive Financial Advisor to Explore Strategic Alternatives
- CRANFORD, N.J. , Jan. 6, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or "the Company") (Nasdaq: CTOR), a majority-owned subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today announced that it has retained Jefferies LLC as its exclusive financial advisor to assist in evaluating strategic alternatives aimed at maximizing shareholder value.
- 01/06/2025
|
Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update
- Clinical and regulatory success in 2024 expected to drive value in 2025 CRANFORD, N.J. , Dec. 27, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today reported business and financial results for the fiscal full year ended September 30, 2024.
- 12/27/2024
|
Citius Pharmaceuticals Reports Productive FDA Type C Meeting to Discuss Phase 3 Mino-Lok® Program and Pathway to Approval
- CRANFORD, N.J. , Nov. 25, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) ("Citius Pharma" or the "Company"), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that the Company held a constructive in-person Type C meeting with the U.S. Food and Drug Administration (FDA).
- 11/25/2024
|
Citius Pharmaceuticals, Inc. Announces 1-for-25 Reverse Stock Split
- CRANFORD, N.J. , Nov. 22, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR) announced today that it will be executing a reverse stock split of its common stock, par value $0.001 per share, at a ratio of 1-for-25 ("Reverse Stock Split").
- 11/22/2024
|
Citius Pharmaceuticals Announces Closing of $3 Million Registered Direct Offering
- CRANFORD, N.J. , Nov. 18, 2024 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius Pharma" or the "Company"), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today closed its previously announced registered direct offering for the purchase of an aggregate of 12,000,000 shares of its common stock and accompanying warrants to purchase up to an aggregate of 12,000,000 shares of its common stock, at a purchase price of $0.25 per share and accompanying warrant.
- 11/18/2024
|
Citius Pharmaceuticals Announces $3 Million Registered Direct Offering
- CRANFORD, N.J. , Nov. 15, 2024 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius Pharma" or the "Company"), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that it has entered into definitive agreements for the purchase of an aggregate of 12,000,000 shares of its common stock and accompanying warrants to purchase up to an aggregate of 12,000,000 shares of its common stock, at a purchase price of $0.25 per share and accompanying warrant in a registered direct offering.
- 11/15/2024
|
Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce Promising Preliminary Results of an Investigator-Initiated Phase I Clinical Trial of Pembrolizumab (KEYTRUDA®) and LYMPHIR™ in Cancer Patients with Recurrent Solid Tumors
- Study, in patients with solid tumors focusing on gynecological malignant tumors such as ovarian, endometrial, and cervical, nearing completion with three remaining subjects to be enrolled 27% Objective Response Rate (ORR) 33% Clinical Benefit Rate (CBR) with a median Progression Free Survival (PFS) of 57 weeks Chemotherapy-free immunomodulatory regimen well-tolerated with no documented serious immune-related adverse events CRANFORD, N.J. , Nov. 11, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR) and Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), today announced promising preliminary results from an ongoing investigator-initiated Phase I clinical trial evaluating the safety and efficacy of a combined regimen of pembrolizumab and LYMPHIR™ (denileukin diftitox-cxdl or E7777) in patients with recurrent solid tumors.
- 11/11/2024
|
Citius Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
- CEO Leonard Mazur to present on Tuesday, September 10, 2024, at 9:00 am ET CRANFORD, N.J. , Sept. 5, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), today announced that Chairman and CEO Leonard Mazur will present and host one-on-one investor meetings at the H.C.
- 09/05/2024
|
Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce LYMPHIR™ (Denileukin Diftitox-cxdl) Added to National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology
- CRANFORD, N.J. , Sept. 5, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR) and Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), today announced that LYMPHIR™ has been added to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®).
- 09/05/2024
|
Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2024 Financial Results and Provides Business Update
- Granted FDA approval of LYMPHIR™ for the treatment of cutaneous T-cell lymphoma Completed merger of oncology subsidiary with TenX Keane; Citius Oncology expected to begin trading on Nasdaq on August 13, 2024, under ticker CTOR Achieved primary and secondary endpoints of Mino-Lok® Phase 3 Trial CRANFORD, N.J. , Aug. 12, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today reported business and financial results for the fiscal third quarter 2024 ended June 30, 2024.
- 08/12/2024
|
Citius Pharmaceuticals Completes Merger of Subsidiary with TenX Keane to form Citius Oncology, Inc.
- LYMPHIR™ for the treatment of cutaneous T-cell lymphoma approved by the FDA Citius Pharmaceuticals, Inc. holds approximately 90% of publicly traded Citius Oncology, Inc. Shares of Citius Oncology, Inc. anticipated to begin trading on Nasdaq under the ticker "CTOR" on August 13, 2024 CRANFORD, N.J., Aug. 12, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that it has completed the previously announced merger of its oncology subsidiary with TenX Keane Acquisition ("TenX") (Nasdaq: TENK), a publicly traded special purpose acquisition company.
- 08/12/2024
|
Citius Pharmaceuticals to Host Investor Call to Discuss Recent and Upcoming Developments
- Management call scheduled for Tuesday, August 13, 2024, at 8:30 AM ET CRANFORD, N.J. , Aug. 12, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), today announced that it will host an investor call on Tuesday, August 13, 2024 at 8:30 am ET to discuss recent and upcoming developments.
- 08/12/2024
|
Citius Pharmaceuticals Receives FDA Approval for LYMPHIR™ (denileukin diftitox-cxdl) Immunotherapy for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma
- Only systemic treatment for relapsed or refractory (r/r) CTCL to target the IL-2 receptor on malignant T-cells and Tregs LYMPHIR is expected to launch within the next five months LYMPHIR's approval marks the first novel targeted systemic therapy approved by the FDA r/r CTCL since 2018 Approval based on Phase 3 Pivotal Study 302 results that demonstrated 36% ORR, reduction in skin disease in 84% of patients, clinically significant pruritis improvement, and no cumulative toxicity CRANFORD, N.J. , Aug. 8, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) ("Citius", "Citius Pharma"), announced today that the U.S. Food and Drug Administration (FDA) has approved LYMPHIR™ (denileukin diftitox-cxdl), a novel immunotherapy for the treatment of r/r cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy.
- 08/08/2024
|
Citius Pharmaceuticals Announces TenX Keane Shareholder Approval of Merger with Citius Oncology, Inc.
- Citius Pharmaceuticals to receive 65.6 million shares of TenX Keane, which will be renamed Citius Oncology, Inc. Citius Pharmaceuticals to retain approximately 90% majority control post transaction Post-merger company expected to trade on Nasdaq as Citius Oncology, Inc. Transaction expected to support commercialization of LYMPHIR, if approved, and exploration of additional oncology assets CRANFORD, N.J. , Aug. 5, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that shareholders of TenX Keane Acquisition ("TenX") (Nasdaq: TENK), a publicly traded special purpose acquisition company, have voted to approve the previously announced business combination with Citius Pharma's oncology subsidiary.
- 08/05/2024
|
Biotech Stocks Race Towards Solutions for Cutaneous T-Cell Lymphoma (CTCL)
- Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - July 18, 2024) - Investorideas.com, a go-to investing platform releases the second of a two-part series looking at biotech/biopharma stocks, featuring Citius Pharmaceuticals, Inc. (NASDAQ: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products. The Company's diversified pipeline includes two late-stage product candidates.
- 07/18/2024
|
Analysts Hunt for Undervalued Biotech Stocks
- Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - July 17, 2024) - Investorideas.com, a go-to investing platform releases the first of a two-part series looking at biotech/biopharma stocks, featuring Citius Pharmaceuticals, Inc. (NASDAQ: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products. The Company's diversified pipeline includes two late-stage product candidates.
- 07/17/2024
|
Bloodstream Infections - From Threats to Solutions
- Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - July 11, 2024) - Investorideas.com, a go-to investing platform releases the second of a two-part series looking at recent news and developments in the blood infections treatment market, featuring Citius Pharmaceuticals, Inc. (NASDAQ: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products. The Company's diversified pipeline includes two late-stage product candidates.
- 07/11/2024
|
Biopharma Stocks Transformative Innovation for the Future of Health
- Vancouver, Kelowna and Delta, British Columbia--(Newsfile Corp. - July 11, 2024) - Investorideas.com, a go-to investing platform releases the first of a two-part series looking at transformative innovation in biopharma, featuring Citius Pharmaceuticals, Inc. (NASDAQ: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products. The Company's diversified pipeline includes two late-stage product candidates.
- 07/11/2024
|
Citius Pharmaceuticals Details Near-Term Milestones for Late-Stage Candidates
- Multiple catalysts for potentially transformative assets in second half of 2024 Strong momentum expected from positive topline results of Phase 3 Mino-Lok® trial, commercialization of LYMPHIR™ if approved First-and-only advantage for Mino-Lok with no current FDA-approved or investigational products; LYMPHIR expected to be additive to current treatment options with mechanism of action supporting market advantage Financial platform and pending oncology spin-off support pipeline development and investment in long-term growth Clinical and operational achievements offer powerful levers for value creation National Sales Director onboarded to recruit and lead the sales organization in preparation for anticipated launch of LYMPHIR CRANFORD, N.J. , July 10, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced expected milestones in the second half of calendar 2024 and recapped key achievements year-to-date Leonard Mazur, Chairman and CEO of Citius stated, "Our solid execution since the beginning of the year sets us up for potentially transformative catalysts in the coming months.
- 07/10/2024
|
Citius Pharmaceuticals to Host Investor Call to Discuss Topline Results of Phase 3 Trial of Mino-Lok Antibiotic Lock Solution
- Management call scheduled for Monday, June 3, 2024 at 8:30 AM ET CRANFORD, N.J. , May 29, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that it will host an investor call on Monday, June 3, 2024 at 8:30 am ET to discuss the topline results of its Phase 3 Trial of Mino-Lok antibiotic lock solution.
- 05/29/2024
|
Why Is Citius Pharmaceuticals (CTXR) Stock Up 11% Today?
- Citius Pharmaceuticals (NASDAQ: CTXR ) stock is on the rise Tuesday after the company announced new results from its Phase 3 clinical trial of Mino-Lok. Mino-Lok is Citius Pharmaceuticals' antibiotic lock solution for patients with central line-associated infections or catheter-related bloodstream infections.
- 05/21/2024
|
Citius Pharmaceuticals Achieves Primary and Secondary Endpoints in Phase 3 Trial of Mino-Lok Antibiotic Lock Solution
- Trial achieves statistically significant primary endpoint (p=0.0006) Secondary endpoint demonstrates statistically significant overall success of Mino-Lok therapy with a greater percentage of patients retaining their catheters (p=0.0025) CRANFORD, N.J. , May 21, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced positive topline results of its pivotal Phase 3 clinical trial of Mino-Lok®, a novel antibiotic lock solution designed to salvage catheters in patients with central line-associated infections (CLABSI) or catheter-related bloodstream infections (CRBSI).
- 05/21/2024
|
CTXR Stock Earnings: Citius Pharma Meets EPS for Q2 2024
- Citius Pharma (NASDAQ: CTXR ) just reported results for the second quarter of 2024. Citius Pharma reported earnings per share of -5 cents.
- 05/14/2024
|
Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2024 Financial Results and Provides Business Update
- Mino-Lok data analysis on track with topline results anticipated this quarter LYMPHIR biologics license application accepted with PDUFA target action date set for August 13, 2024 CRANFORD, N.J. , May 14, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today reported business and financial results for the fiscal second quarter 2024 ended March 31, 2024.
- 05/14/2024
|
Citius Pharmaceuticals to Participate in Upcoming EF Hutton and H.C. Wainwright Investor Conferences
- CRANFORD, N.J. , May 10, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced its participation in two upcoming investor conferences.
- 05/10/2024
|
Citius Pharmaceuticals Announces Closing of $15 Million Registered Direct Offering
- CRANFORD, N.J. , April 30, 2024 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius" or the "Company"), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that it has closed its previously announced registered direct offering for the purchase of an aggregate of 21,428,574 shares of its common stock and accompanying warrants to purchase up to an aggregate of 21,428,574 shares of its common stock, at a purchase price of $0.70 per share and accompanying warrant.
- 04/30/2024
|
Citius Pharmaceuticals Announces $15 Million Registered Direct Offering
- CRANFORD, N.J. , April 26, 2024 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius" or the "Company"), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that it has entered into definitive agreements for the purchase of an aggregate of 21,428,574 shares of its common stock and accompanying warrants to purchase up to an aggregate of 21,428,574 shares of its common stock, at a purchase price of $0.70 per share and accompanying warrant in a registered direct offering.
- 04/26/2024
|
Citius Pharmaceuticals Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell Lymphoma
- National Cancer Institute (NCI)-designated research and treatment center City of Hope, in Duarte, CA, to participate in the University of Minnesota (UMN) Masonic Cancer Center's ongoing Phase 1 trial to determine the maximum tolerated dose of LYMPHIR plus CAR-T therapy CRANFORD, N.J. , April 11, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company developing and commercializing first-in-class critical care products, today announced that the University of Minnesota Masonic Cancer Center intends to expand their ongoing investigator-initiated Phase 1 trial of LYMPHIR™ (denileukin diftitox) in combination with FDA-approved CAR-T products for the treatment of B-cell lymphomas.
- 04/11/2024
|
Citius Pharmaceuticals to Present at the LD Micro Invitational XIV Investor Conference
- CRANFORD, N.J. , April 4, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that Chairman and CEO Leonard Mazur will present at the 14th Annual LD Micro Invitational investor conference being held April 8-9, 2024, in New York City.
- 04/04/2024
|
Citius Pharmaceuticals Announces FDA Acceptance of the BLA Resubmission of LYMPHIR™ (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma
- FDA assigns Prescription Drug User Fee Act (PDUFA) target action date of August 13, 2024 CRANFORD, N.J., March 18, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today announced that the U.S. Food and Drug Administration (FDA) has accepted the resubmission of the Company's Biologics License Application (BLA) for LYMPHIR™ (denileukin diftitox), an IL-2-based immunotherapy for the treatment of patients with relapsed or refractory cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy.
- 03/18/2024
|
Citius Pharmaceuticals, Inc. Secures $2.4 million through New Jersey Economic Development Program
- Net operating losses converted into non-dilutive capital CRANFORD, N.J. , March 7, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today announced that the Company has received $2.4 million in non-dilutive capital through New Jersey's Technology Business Tax Certificate Transfer Program, more commonly known as the Net Operating Loss (NOL) Program, funded through the New Jersey Economic Development Authority (NJEDA).
- 03/07/2024
|
Citius Pharmaceuticals Announces Filing of Form S-3 Shelf Registration Statement to Replace Expiring Prior Shelf Registration
- CRANFORD, N.J. , Feb. 26, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that the Company filed a Form S-3 shelf registration on February 23, 2024 with the Securities and Exchange Commission to replace its currently effective shelf registration statement that expires in April 2024 pursuant to SEC rules.
- 02/26/2024
|
Citius Pharmaceuticals to Participate in Upcoming BIO CEO and Sidoti Investor Conferences
- CRANFORD, N.J. , Feb. 23, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced its participation in two upcoming investor conferences.
- 02/23/2024
|
Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2024 Financial Results and Provides Business Update
- Resubmitted LYMPHIR™ Biologics License Application; awaiting PDUFA date Completed enrollment in the Mino-Lok® Pivotal Phase 3 trial CRANFORD, N.J. , Feb. 14, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today reported business and financial results for the fiscal first quarter 2024 ended December 31, 2023.
- 02/14/2024
|
Citius Pharmaceuticals Resubmits the Biologics License Application of LYMPHIR™ (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma
- FDA acceptance of the completed resubmission package and issuance of a Prescription Drug User Fee Act (PDUFA) date is expected within 30 days of resubmission CRANFORD, N.J. , Feb. 13, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today announced the resubmission of the Company's Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for LYMPHIR™ (denileukin diftitox), an IL-2-based immunotherapy for the treatment of patients with relapsed or refractory cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy.
- 02/14/2024
|
Citius Pharmaceuticals Announces Nomination of Pharmaceutical Executive Robert J. Smith to its Board of Directors
- Independent Director nominee expected to be elected at Annual Shareholders' Meeting in March 2024 CRANFORD, N.J. , Jan. 23, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today announced the nomination of seasoned pharmaceutical executive Robert J.
- 01/23/2024
|
Citius Pharmaceuticals Completes Enrollment in Pivotal Phase 3 Trial of its Mino-Lok® Therapeutic to Salvage Catheters
- Topline results expected 2Q 2024 Study enrolled a total of 241 patients; 109 catheter failures observed First-and-only antibiotic lock solution in development to salvage catheters in patients with CRBSI CRANFORD, N.J., Jan. 2, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that it has completed enrollment in its pivotal Phase 3 clinical trial for Mino-Lok®, an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections.
- 01/02/2024
|
Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2023 Financial Results and Provides Business Update
- Mino-Lok® Pivotal Phase 3 trial enrollment completed; topline data expected 2Q 2024 LYMPHIR™ BLA resubmission on track for early 2024 CRANFORD, N.J. , Jan. 2, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today reported business and financial results for the fiscal full year ended September 30, 2023.
- 01/02/2024
|
Citius Pharmaceuticals to Participate in the Sidoti Micro-Cap Virtual Conference on November 15, 2023
- CRANFORD, N.J. , Nov. 9, 2023 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company developing and commercializing first-in-class critical care products, today announced that Chairman and CEO Leonard Mazur will present at the Sidoti Micro-Cap Virtual Conference on November 15, 2023.
- 11/09/2023
|
Citius Pharmaceuticals Announces Publication in Frontiers of Immunology of Positive Results from Solid Tumor Study of LYMPHIR™ in Combination with Checkpoint Inhibitor
- Preclinical study demonstrates that adding LYMPHIR to anti-PD-1 treatment augments anti-tumor activity and improves overall survival compared to monotherapy alone by transiently depleting Tregs in the tumor microenvironment CRANFORD, N.J. , Oct. 31, 2023 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR) today announced that preclinical research on LYMPHIR ("denileukin diftitox" or "E7777") was published today in Frontiers in Immunology 1, a leading peer-reviewed journal in the immunology field.
- 10/31/2023
|
Citius Pharmaceuticals Executes Definitive Agreement to Merge Wholly Owned Subsidiary with TenX Keane Acquisition to Form Publicly Listed Citius Oncology, Inc.
- Citius Pharmaceuticals, Inc. to receive $675 million in equity of Citius Oncology, Inc. and retain approximately 90% majority control in publicly listed Citius Oncology, Inc. post transaction Transaction anticipated to close in the first half of 2024 CRANFORD, N.J. and NEW YORK , Oct. 24, 2023 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company developing and commercializing first-in-class critical care products, and TenX Keane Acquisition ("TenX") (NASDAQ: TENKU), a publicly traded special purpose acquisition company (SPAC), today announced that they have entered into a definitive agreement, dated October 23, 2023, for a proposed merger of TenX and Citius Pharma's wholly owned oncology subsidiary that will continue as a public company listed on the Nasdaq exchange.
- 10/24/2023
|
Citius Pharmaceuticals Reschedules Participation in Sidoti Small-Cap Virtual Investor Conference for November 2023
- CRANFORD, N.J. , Sept. 18, 2023 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, has rescheduled its participation in Sidoti's Small-Cap Virtual Conference to November 2023 due to funeral services for the late Howard Safir, a long-time member of the Citius Board.
- 09/18/2023
|
Citius Pharmaceuticals to Participate in H.C. Wainwright and Sidoti Investor Conferences in September 2023
- CRANFORD, N.J. , Sept. 6, 2023 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced its participation in two investor conferences in September 2023.
- 09/06/2023
|
Citius Pharmaceuticals: Steer Clear From This One
- The article provides an updated analysis of Citius Pharmaceuticals following a previous piece in February 2023. Citius' lead therapy has a midsummer 2023 PDUFA; it has generated excitement among investors, although it is unlikely to generate alpha. Its second lead therapy is likely to disappoint.
- 06/02/2023
|
Citius Pharmaceuticals to Present at the Sidoti Micro-Cap Virtual Conference on January 18, 2023
- CRANFORD, N.J. , Jan. 11, 2023 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that Chairman and CEO Leonard Mazur will present at the Sidoti Micro-Cap Virtual Conference on January 18, 2023.
- 01/11/2023
|
After Plunging -30.6% in 4 Weeks, Here's Why the Trend Might Reverse for Citius Pharmaceuticals, Inc. (CTXR)
- The heavy selling pressure might have exhausted for Citius Pharmaceuticals, Inc. (CTXR) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
- 12/28/2022
|
Citius Pharmaceuticals: Large Price Action Imminent From Catalysts Within 60 Days
- Citius Pharmaceuticals, Inc. has a handful of catalysts set to occur in the next few months. Of these, some are critical to extending its cash runway far enough to reach commercialization of its major products, and are therefore a "must complete" by the company.
- 11/08/2022
|
Citius Pharmaceuticals, Inc. to Present at the H.C. Wainwright 24th Annual Global Investment Conference
- UPDATED: Chairman & CEO of Citius, Leonard Mazur, to present September 12, 2022 at 8:30am ET CRANFORD, N.J. , Sept. 8, 2022 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), today announced that Citius will participate in the H.C.
- 09/08/2022
|
Citius Pharmaceuticals: Hoping For A Turnaround Strategy
- Citius Pharmaceuticals is yet to release test results a year after it was granted positive recommendation by the Independent Data Monitoring Committee (IDMC) to proceed with the planned trial. With the help of Biorasi, Citius could reach full patient enrolment by the end of 2022, as earlier indicated.
- 07/05/2022
|
Citius Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference on May 24, 2022
- CRANFORD, N.J. , May 18, 2022 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company developing and commercializing first-in-class critical care products, today announced that it will present at the H.C.
- 05/18/2022
|
3 Reddit Stocks to Buy in May
- These trending Reddit stocks have considerable growth catalysts in motion, offering healthy upside potential in May and beyond The post 3 Reddit Stocks to Buy in May appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS It doesn't matter if you have $500 in savings or $5 million.
- 05/08/2022
|
Citius Pharmaceuticals to Present at the NobleCon18 Investor Conference on April 20, 2022
- CRANFORD, N.J. , April 14, 2022 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products in oncology, anti-infectives in adjunct cancer care, unique prescription products, and stem cell therapies, today announced that it will present at NobleCon18, Noble Capital Markets' 18th Annual Investor Conference being held April 19-21, 2022.
- 04/14/2022
|
Citius (CTXR) Posts Top-Line Data From Pivotal Lymphoma Study
- Citius (CTXR) releases encouraging top-line data from the phase III study on I/ONTAK for the treatment of persistent or recurrent cutaneous T-cell lymphoma.
- 04/07/2022
|
Trading Penny Stocks on April 6th, MOBQ Stock Pushes Up
- Here's what you need to know about trading penny stocks on April 6th The post Trading Penny Stocks on April 6th, MOBQ Stock Pushes Up appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 04/06/2022
|
Shares of Citius jump 18% on new data for experimental lymphoma drug
- Shares of Citius Pharmaceuticals Inc. CTXR, -1.60% were up 18.5% in premarket trading on Wednesday after the company shared positive topline data from a Phase 3 clinical trial for its experimental treatment for cutaneous T-cell lymphoma, which is a type of non-Hodgkin lymphoma. Citius said it plans to submit an application for approval of the investigational therapy, I/Ontak, to the Food and Drug Administration in the second half of this year based on this data.
- 04/06/2022
|
Citius: 2022 Is A Year Of Catalysts
- 5 Active Programs With Near Term Catalysts.
- 03/28/2022
|
Citius Pharmaceuticals, Inc. to Present at Upcoming March 2022 Conferences
- CRANFORD, N.J., March 3, 2022 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products with a focus on oncology, anti-infective products in adjunct cancer care, unique prescription products, and stem cell therapies, today announced that it will be presenting at two investor conferences in March 2022.
- 03/03/2022
|
Biotech Penny Stocks To Buy For Under $5 As Russia Ukraine Conflict Heats Up
- Biotech penny stocks to watch as Ukraine-Russia conflict builds steam. The post Biotech Penny Stocks To Buy For Under $5 As Russia Ukraine Conflict Heats Up appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 02/17/2022
|
Citius Pharmaceuticals to Host Key Opinion Leader Webcast on the Compelling Need to Salvage Central Venous Catheters in CLABSI Patients
- CRANFORD, N.J., Oct. 25, 2021 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products with a focus on oncology, anti-infective products in adjunct cancer care, unique prescription products, and stem cell therapies, today announced that it will host a key opinion leader (KOL) webinar on the compelling need to salvage central venous catheters in patients with central line associated blood stream infections (CLABSI) on Thursday, November 11, 2021 at 11:30am Eastern Time.
- 10/25/2021
|
Top Penny Stocks to Add to Your Watchlist This Week
- Which penny stocks are on your watchlist for this coming week? The post Top Penny Stocks to Add to Your Watchlist This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 10/17/2021
|
Citius Pharmaceuticals to Host Investor Webcast to Discuss the Acquisition of Late Phase 3 Cancer Immunotherapy I/ONTAK (E7777)
- CRANFORD, N.J., Oct. 13, 2021 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR) today announced that it will host a webcast on October 20, 2021 at 8:30 a.m.
- 10/13/2021
|
Citius Pharmaceuticals to Present at Upcoming October Investor Conferences
- CRANFORD, N.J., Oct. 6, 2021 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products with a focus on oncology, anti-infective products in adjunct cancer care, unique prescription products, and stem cell therapies, today announced that it will present at two investor conferences during the month of October 2021.
- 10/06/2021
|
Temple University Renames College of Liberal Arts Main Campus Building in Honor of Citius Pharmaceuticals Executive Chairman Leonard Mazur
- CRANFORD, N.J., Oct. 1, 2021 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products with a focus on oncology, anti-infective products in adjunct cancer care, unique prescription products, and stem cell therapies, today announced that Citius Executive Chairman Leonard Mazur and his wife, Helena Mazur, were honored by Temple University , Philadelphia, PA, which renamed the main building housing the College of Liberal Arts (CLA) to Leonard and Helena Mazur Hall in recognition of the Mazur's longstanding commitment to Temple University's students and alumni.
- 10/01/2021
|
Citius Pharmaceuticals to Join Benzinga All Access Show on Friday, September 17, 2021
- CRANFORD, N.J., Sept. 14, 2021 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products with a focus on oncology, anti-infective products in adjunct cancer care, unique prescription products and stem cell therapies, today announced that it will be joining Benzinga's All Access Show for a 20-minute interview on Friday, September 17, 2021 at 10:10 am ET.
- 09/14/2021
|
Citius Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference September 13-15
- CRANFORD, N.J., Sept. 8, 2021 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products with a focus on oncology, anti-infective products in adjunct cancer care, unique prescription products and stem cell therapies, today announced that it will present at the H.C.
- 09/08/2021
|
Best Penny Stocks For Your Buy List in September? 3 To Watch
- With September only a day away, which penny stocks are on your buy list? The post Best Penny Stocks For Your Buy List in September?
- 08/31/2021
|
Top Penny Stocks You Need to Know About Right Now
- Are these top penny stocks on your small-caps watchlist The post Top Penny Stocks You Need to Know About Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 08/20/2021
|
Citius Pharmaceuticals, Inc. Reports Third Fiscal Quarter 2021 Financial Results and Provides General Business Update
- CRANFORD, N.J., Aug. 12, 2021 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products with a focus on anti-infective products in adjunct cancer care, unique prescription products and stem cell therapy, today reported financial results for the third fiscal quarter of 2021 ended June 30, 2021, and provided a general business update.
- 08/12/2021
|
Citius Pharmaceuticals Addresses Unmet Needs for Patients with CVCs
- Image by falco from Pixabay What happens when the one product keeping you alive becomes infected?
- 08/04/2021
|
Best Reddit Penny Stocks to Buy in August? 3 For Your List
- There's a reason that so many investors like Reddit penny stocks; here's 3 for your list The post Best Reddit Penny Stocks to Buy in August? 3 For Your List appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 07/22/2021
|
Could Citius Pharmaceuticals Be a Millionaire-Maker Stock?
- A lot would have to go right for this biotech to make investors rich.
- 07/20/2021
|
3 Penny Stocks That Are Popular With Reddit Traders Right Now
- These Reddit Penny Stocks Are Rising in Popularity Right Now; Are They Worth It or Not? The post 3 Penny Stocks That Are Popular With Reddit Traders Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 07/15/2021
|
7 Top-Rated Pharmaceutical Companies to Invest In for July
- Pharma stocks like MNMD stock and ANVS stock offer investors long-term growth potential in a market on track to hit a value of $1.70 trillion. The post 7 Top-Rated Pharmaceutical Companies to Invest In for July appeared first on InvestorPlace.
- 07/09/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Citius Pharmaceuticals, Inc. - CTXR
- NEW YORK, July 7, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Citius Pharmaceuticals, Inc. ("Citrus" or the "Company") (NASDAQ: CTXR). Such investors are advised to contact Robert S.
- 07/07/2021
|
Making a List of Penny Stocks to Buy? Here's 7 to Watch in Summer 2021
- Does your list of penny stocks to watch include these 7 hot small-caps? The post Making a List of Penny Stocks to Buy?
- 07/07/2021
|
Citius Pharmaceuticals, Inc. Provides First Half 2021 Business Update, Highlights Upcoming Milestones
- CRANFORD, N.J., July 7, 2021 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products with a focus on anti-infective products in adjunct cancer care, unique prescription products and stem cell therapy, today provided a business update for the six-month period ended June 30, 2021 and reported on recent corporate developments.
- 07/07/2021
|
Are Options Traders Betting on a Big Move in Citius Pharmaceuticals (CTXR) Stock?
- Investors need to pay close attention to Citius Pharmaceuticals (CTXR) stock based on the movements in the options market lately.
- 07/07/2021
|
Here's Why Citius Pharmaceuticals Stock Is Losing Ground Today
- Another interim analysis has come and gone with an unsatisfying result.
- 07/01/2021
|
7 Reddit Penny Stocks to Watch for Big Upside Ahead
- If we've learned anything from the Reddit in January, it's not to underestimate them. These 7 Reddit penny stocks have good upsides.
- 06/28/2021
|
Is It Too Late to Buy Citius Pharmaceuticals Stock?
- See if this biotech has what takes to climb even higher.
- 06/23/2021
|
Which Penny Stocks Are the Best to Buy Right Now? 3 to Watch in 2021
- Looking for penny stocks to buy in July 2021? Check these 3 for your watchlist The post Which Penny Stocks Are the Best to Buy Right Now?
- 06/18/2021
|
Top 3 Penny Stocks to Buy Right Now for Your 2021 Summer Watchlist
- Best Penny Stocks to Watch in Summer 2021 With Summer upon us, which penny stocks are investors buying right now? Well, there are quite a few answers to this question.
- 06/16/2021
|
CTXR Stock Price Increases Over 10%: Why It Happened
- The stock price of Citius Pharmaceuticals Inc (NASDAQ: CTXR) increased by over 10% during intraday trading. This is why it happened.
- 06/15/2021
|
Citius: Halt For Superiority On The Horizon
- IDMC meets on June 29 for Superiority review. Mino-Lok has no competition.
- 06/15/2021
|
Citius Pharmaceuticals Expands Scientific Advisory Board with Addition of Dr. John Laffey, Expert in Stem Cell and Gene Therapies for ARDS
- CRANFORD, N.J., June 15, 2021 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products with a focus on anti-infective products in adjunct cancer care, unique prescription products and stem cell therapy, today announced that Dr. John Laffey, a leading scholar in Acute Respiratory Distress Syndrome (ARDS) and the use of cutting-edge therapies to treat acute lung disorders, has been appointed to its ARDS Scientific Advisory Board (SAB), effective immediately.
- 06/15/2021
|
4 Top Biotech Penny Stocks To Watch In The Second Half Of June 2021
- If biotech penny stocks are your focus, check these 4 out right now The post 4 Top Biotech Penny Stocks To Watch In The Second Half Of June 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 06/14/2021
|
Citius Pharmaceuticals to be Added to Russell 2000® Index
- CRANFORD, N.J., June 7, 2021 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products with a focus on anti-infective products in adjunct cancer care, unique prescription products and stem cell therapy, today announced that it is set to be added to the Russell 2000® Index at the conclusion of the Russell US Indexes annual reconstitution, effective at the opening of the U.S. equity markets on June 28, 2021.
- 06/07/2021
|
Citius Pharmaceuticals Introduces Milo-Lok
- Specialty pharmaceutical company Citius Pharmaceuticals is dedicated to developing and commercializing therapeutic products for growing markets. Citius' President and CEO Myron Holubiak spoke about the company's four pipeline programs – Milo-Lok, Halo-Lido, Mino-Wrap and iMSC – at the Benzinga Global Small Cap Business Conference on May 13, 2021.
- 06/03/2021
|
Citius Pharmaceuticals Selected to Receive Best Poster Award at the International Society for Cell and Gene Therapy 2021 Annual Meeting
- CRANFORD, N.J., May 25, 2021 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products with a focus on anti-infective products in adjunct cancer care, unique prescription products and stem cell therapy, today announced that it has received the Best Poster Award at the prestigious International Society for Cell and Gene Therapy (ISCT) 2021 Annual Meeting.
- 05/25/2021
|
Penny Stocks to Buy? 3 That WallStreetBets Won't Stop Talking About
- 3 penny stocks that are wildly popular on Reddit and WallStreetBets The post Penny Stocks to Buy? 3 That WallStreetBets Won't Stop Talking About appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 05/20/2021
|
Citius Pharmaceuticals to Feature Updated Positive Interim Results of i-MSC Study During Poster Presentation at International Society for Cell and Gene Therapy
- CRANFORD, N.J., May 18, 2021 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products with a focus on anti-infective products in adjunct cancer care, unique prescription products and stem cell therapy, today announced that it will present a poster at the International Society for Cell and Gene Therapy (ISCT) Annual Meeting, to be held virtually May 26-28, 2021.
- 05/18/2021
|
Citius Pharmaceuticals, Inc. Announces Appointment of Ilanit Allen as Vice President, Corporate Communications and Investor Relations
- CRANFORD, N.J., May 17, 2021 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR) today announced that Ilanit Allen has been appointed Vice President of Corporate Communications and Investor Relations, effective immediately.
- 05/17/2021
|
5 Reddit Penny Stocks Seeing the Most Chatter Friday
- InvestorPlace is closing out a busy week of trading with a look at the Reddit penny stocks seeing the most chatter on Friday. The post 5 Reddit Penny Stocks Seeing the Most Chatter Friday appeared first on InvestorPlace.
- 05/14/2021
|
EXCLUSIVE: Citius Pharmaceuticals CEO Myron Holubiak Talks Company Advantages
- Myron Holubiak, president and CEO of Citius Pharmaceuticals Inc (NASDAQ: CTXR), appeared Thursday at Benzinga's Global Small Cap Conference for an exclusive interview. The name Citius Pharmaceuticals comes from the Olympic motto "Citius, Altius, Fortius," which is Latin for "Faster, Higher, Stronger," Holubiak told Benzinga.
- 05/13/2021
|
Citius Pharmaceuticals, Inc. Reports Second Fiscal Quarter 2021 Financial Results and Provides General Business Update
- CRANFORD, N.J., May 13, 2021 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR) today reported financial results for the second fiscal quarter of 2021 and provided a general business update.
- 05/13/2021
|
Citius Pharmaceuticals to Participate in Fireside Chat at the Gabelli Funds Virtual Microcap Symposium on Tuesday, May 18
- CRANFORD, N.J., May 11, 2021 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR) today announced that it will participate in a fireside chat at the Gabelli Funds Virtual Microcap Symposium.
- 05/11/2021
|
5 Reddit Penny Stocks Seeing the Most Chatter Tuesday
- We're taking another dive into the world of penny stocks on Tuesday with a look at Reddit's most-talked-about for the day. The post 5 Reddit Penny Stocks Seeing the Most Chatter Tuesday appeared first on InvestorPlace.
- 05/11/2021
|
Trending Penny Stocks To Watch in 2021? Take a Look At These
- Best penny stocks to watch in 2021? Here are 3 for your long term watchlist The post Trending Penny Stocks To Watch in 2021?
- 05/04/2021
|
5 Reddit Penny Stocks Seeing the Most Chatter Tuesday
- We're diving back into the world of penny stocks again today as we look at those that are getting the most discussion over on Reddit. The post 5 Reddit Penny Stocks Seeing the Most Chatter Tuesday appeared first on InvestorPlace.
- 05/04/2021
|
5 Reddit Penny Stocks Seeing the Most Chatter Thursday
- Investors can seem to get enough of Reddit penny stocks news and we're looking at the most talked-about ones for Thursday. The post 5 Reddit Penny Stocks Seeing the Most Chatter Thursday appeared first on InvestorPlace.
- 04/29/2021
|
Hot Penny Stocks to Watch; Is it Time to Buy The Biotech Dip?
- Penny stocks present opportunities to buy the dip often; is that the case with these biotech stocks? The post Hot Penny Stocks to Watch; Is it Time to Buy The Biotech Dip?
- 04/29/2021
|
Citius Pharmaceuticals Reports Strong Clinical Community Engagement During Mino-Lok® Phase 3 Trial-Related Webinar
- CRANFORD, N.J., April 29, 2021 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company dedicated to the development and commercialization of critical care products with a focus on anti-infective products in adjunct cancer care, unique prescription products and stem cell therapy, today announced updates delivered during its third Mino-Lok® Phase 3 trial-related webinar.
- 04/29/2021
|
5 Reddit Penny Stocks Seeing the Most Chatter Tuesday
- Reddit penny stocks are still all the rage from investors that aren't afraid of risks and we're taking a look at the most talked about today. The post 5 Reddit Penny Stocks Seeing the Most Chatter Tuesday appeared first on InvestorPlace.
- 04/27/2021
|
Citius Pharmaceuticals CEO Myron Holubiak Featured in Benzinga Interview
- CRANFORD, N.J., April 22, 2021 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company dedicated to the development and commercialization of critical care products with a focus on anti-infective products in adjunct cancer care, unique prescription products and stem cell therapy, today announced that Citius President and CEO, Myron Holubiak, was featured in an interview with Benzinga discussing the Company's product pipeline, the impact of Covid-19, and upcoming milestones.
- 04/22/2021
|
5 Reddit Penny Stocks Seeing the Most Chatter Thursday
- Reddit penny stocks continue to be a hot topic among investors looking to take out investments in companies without having to break the bank. The post 5 Reddit Penny Stocks Seeing the Most Chatter Thursday appeared first on InvestorPlace.
- 04/22/2021
|
7 Reddit Penny Stocks to Buy for a Biotech Boom
- So, which biotech penny stocks, popular with the Reddit set, offer such opportunity? Consider these seven as ones with potential to live up to online enthusiasm.
- 04/16/2021
|
Reddit Penny Stocks That Actually Look Pretty Reasonable
- Yes, these Reddit penny stocks are all reasonably risky plays. But there is growth potential in each of these companies.
- 04/13/2021
|
5 Reddit Penny Stocks Seeing the Most Chatter Friday
- Reddit penny stocks continue to be a hot subject among retail investors and we're looking at the most-talked-about ones today. The post 5 Reddit Penny Stocks Seeing the Most Chatter Friday appeared first on InvestorPlace.
- 04/09/2021
|
Exclusive: Citius Pharmaceuticals Exec Chairman On Product Pipeline, Potential $1B TAM
- Citius Pharmaceuticals Inc. (NASDAQ: CTXR) Executive Chairman Leonard Mazur told Benzinga CEO Jason Raznick Thursday that he's invested $26.5 million of his own money in the specialty pharmaceutical company. Citius is comprised of "all-in entrepreneurs," Mazur said on Benzinga's "Power Hour" YouTube show.
- 04/08/2021
|
Capital Raises and Clinical Programs Prove the Progress of Citius Pharmaceuticals
- It's a great time to hold CTXR stock as the company's CEO shares his vision of significant corporate developments and clinical progress. The post Capital Raises and Clinical Programs Prove the Progress of Citius Pharmaceuticals appeared first on InvestorPlace.
- 03/22/2021
|
10 Reddit Penny Stocks Seeing the Most Chatter Today
- Reddit penny stocks continue to be of interest to risky investors and InvestorPlace is looking at the top ones for Monday. The post 10 Reddit Penny Stocks Seeing the Most Chatter Today appeared first on InvestorPlace.
- 03/22/2021
|
7 Reddit Penny Stocks Seeing the Most Chatter Today
- Retail investors over on Reddit Penny Stocks are showing interest in quite a few interesting players today that investors will want to note. The post 7 Reddit Penny Stocks Seeing the Most Chatter Today appeared first on InvestorPlace.
- 03/18/2021
|
CTXR Stock Price Increases Over 10% Pre-Market: Why It Happened
- The stock price of Citius Pharmaceuticals Inc (NASDAQ: CTXR) is trading at over 10% pre-market. This is why it happened.
- 02/22/2021
|
Citius Pharmaceuticals Announces Closing of $76.5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
- CRANFORD, N.J., Feb. 19, 2021 /PRNewswire/ -- Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) ("Citius" or the "Company"), a specialty pharmaceutical company focused on developing and commercializing critical care drug products, today announced that it has closed its previously announced sale...
- 02/19/2021
|
CTXR Stock: 9 Things to Know About the Biotech Citius Pharma as Shares Surge
- Citius Pharmaceuticals (CTXR) stock is on the rise Friday with heavy trading of its shares despite a lack of news about the company today. The post CTXR Stock: 9 Things to Know About the Biotech Citius Pharma as Shares Surge appeared first on InvestorPlace.
- 02/19/2021
|
CTXR Stock Price Increases Over 25% Pre-Market: Why It Happened
- The stock price of Citius Pharmaceuticals Inc (NASDAQ: CTXR) is trading at over 25% pre-market. This is why it happened.
- 02/19/2021
|
Citius Pharmaceuticals Announces $76.5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
- CRANFORD, N.J., Feb. 17, 2021 /PRNewswire/ -- Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) ("Citius" or the "Company"), a specialty pharmaceutical company focused on developing and commercializing critical care drug products, today announced that it has entered into definitive agreements...
- 02/17/2021
|
Citius Pharmaceuticals Issues Shareholder Letter with Corporate Update on Recent Achievements and Anticipated Milestones for 2021
- CRANFORD, N.J., Feb. 16, 2021 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company developing and commercializing critical care drug products, today issued a shareholder letter providing a corporate update on the...
- 02/16/2021
|
Citius Pharmaceuticals Announces Closing of $20.0 Million Private Placement Offering Priced At-the-Market
- CRANFORD, N.J., Jan. 27, 2021 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company focused on developing and commercializing critical care drug products, today announced that it has closed on the sale to certain...
- 01/27/2021
|
Citius Pharmaceuticals Receives FDA Response and Guidance to Pre-IND Consultation Submission for Mino-Wrap
- CRANFORD, N.J., Dec. 9, 2020 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company focused on developing and commercializing critical care drug products, announced its receipt of a written response and guidance from the...
- 12/09/2020
|
Citius Announces Results of Study that Mino-Lok Eradicates S. aureus Biofilm More Effectively and Expeditiously than Components
- CRANFORD, N.J., Nov. 30, 2020 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company focused on developing and commercializing critical care drug products, today announced the completion of a Boston Analytical study...
- 11/30/2020
|
Citius Pharmaceuticals to Present at H.C. Wainwright 6th Annual Israel Conference
- CRANFORD, N.J., Nov. 9, 2020 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company developing and commercializing critical care drug products, today announced that it will present at the H.C. Wainwright 6th Annual...
- 11/09/2020
|
Let me enjoy the moment: Chirag Paswan after deciding to go solo in Bihar polls
- Bihar assembly polls: The LJP will put up candidates against Nitish Kumar's JDU.The party will not field its candidates against the Bharatiya Janata Party (BJP)
- 10/05/2020
|
Bihar Assembly Election 2020: Let me enjoy the moment, says LJP chief Chirag Paswan after deciding to go solo in Bihar
- The Bihar assembly polls will be held in three phases on October 28, November 3, and November 7, and the counting of votes will take place on November 10.
- 10/05/2020
|
"Let Me Enjoy The Moment": Chirag Paswan After Deciding To Go Solo In Bihar
- The Lok Janshakti Party(LJP) on Sunday announced, after a meeting here in New Delhi its decision to go solo in the ensuing assembly election in Bihar.
- 10/04/2020
|
Bills introduced in Lok Sabha, Rajya Sabha elects dy chairman | Day-1 of Parliament's Monsoon Session
- The Monsoon Session of Parliament began on September 14 under the shadow of coronavirus. Rajya Sabha is set to resume at 9 am and Lok Sabha at 3 pm on Tuesday.
- 09/14/2020
|
Parliament's Monsoon Session begins; Congress notice over Chinese incursion in Ladakh
- The Monsoon session 2020 of Parliament is set to commence today, i.e. Monday. The fourth session of the 17th Lok Sabha and 252nd session of Rajya Sabha is scheduled to be held today and subject to exigencies of government business, may conclude on October 1.
- 09/14/2020
|
Letter vs letter: Show of loyalty via copy and paste
- The letter, first written by Leader of Congress party in Lok Sabha Adhir Ranjan Chowdhury to Congress president Sonia Gandhi, declares “unequivocal and complete faith” in her leadership.
- 08/24/2020
|
Citius Pharmaceuticals to Present at the MoneyShow Las Vegas Virtual Expo
- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company focused on developing and commercializing critical care drug products, announced today that the company will deliver a presentation at the MoneyShow Las Vegas Virtual Expo that is being held August 18 – 20, 2020.
- 08/13/2020
|
Citius Pharmaceuticals Announces Closing of $9.6 Million Bought Deal Offering and Full Exercise of Underwriter's Option to Purchase Additional Shares
- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company focused on developing and commercializing critical care drug products, announced today the closing of its previously announced underwritten public offering of 9,159,524 shares of common stock of the Company, including the exercise in full by the underwriter of the option to purchase an additional 1,194,720 shares of common stock, at a price to the public of $1.05 per share.
- 08/10/2020
|
Citius Pharmaceuticals Announces $6.0 Million Bought Deal Offering
|
Citius Pharmaceuticals Announces $6.0 Million Bought Deal Offering
- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company focused on developing and commercializing critical care drug products, announced today that it has entered into an underwriting agreement with H.C. Wainwright & Co., LLC under which the underwriter has agreed to purchase on a firm commitment basis 5,714,286 shares of common stock of the Company, at a price to the public of $1.05 per share, less underwriting discounts and commissions. The closing of the offering is expected to occur on or about August 10, 2020, subject to satisfaction of customary closing conditions.
- 08/05/2020
|
LD Micro - Announces Preliminary List of Presenters for the LD-500
- LOS ANGELES, CA / ACCESSWIRE / August 5, 2020 / LD Micro today announced the initial list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively online.
- 08/05/2020
|
Citigroup promotes Singapore bank head to oversee wealth business in Asia
- Your source for credible news and authoritative insights from Hong Kong, China and the world.
- 08/05/2020
|
iPhone SE, other phones to be discounted during Flipkart Big Saving Days sale
- In addition to Amazon, Flipkart is also hosting the Big Saving Days sale starting August 6. Here are some of the best deals on phones.
- 08/05/2020
|
Danaos Corporation's (DAC) CEO John Coustas on Q2 2020 Results - Earnings Call Transcript
- Danaos Corporation (NYSE:DAC) Q2 2020 Earnings Conference Call August 4, 2020 9:00 AM ET Company Participants Evangelos Chatzis - Chief Financial Officer John Coustas - President and Chief Executive Officer Conference Call Participants Randy Giveans - Jefferies LLC Christian Wetherbee - Citigroup Inc.
- 08/05/2020
|
Citibank names Singapore retail banking head, carves new role for retail high-net-worth clients
- SINGAPORE (THE BUSINESS TIMES) - Citi has made two internal senior retail banking appointments in Asia-Pacific that are based in Singapore, including a newly created role with oversight of the bank's retail high-net-worth clients, as well as a new head for its Singapore retail banking arm.. Read more at straitstimes.com.
- 08/05/2020
|
Citibank names Singapore retail banking head, carves new role for retail HNW segment
- CITI has made two internal senior retail banking appointments in Asia Pacific that are based in Singapore, including a newly created role with oversight of the bank’s retail high-net worth clients as well as a new head for its Singapore retail banking arm. Read more at The Business Times.
- 08/05/2020
|
Itaú Unibanco Holding (ITUB) Q2 2020 Earnings Call Transcript | The Motley Fool
- ITUB earnings call for the period ending June 30, 2020.
- 08/05/2020
|
Silver is set to outperform gold. Here's why
- Silver is set to outshine gold, even as both precious metals soar in the midst of a faltering global economy and a weakening U.S. dollar.
- 08/05/2020
|
Regency Centers Corp (REG) Q2 2020 Earnings Call Transcript | The Motley Fool
- REG earnings call for the period ending June 30, 2020.
- 08/05/2020
|
Banking-BigTech Deals Are on the Rise: Citi Partners with Amazon - Finovate
- Point of sale financing is all the rage in fintech right now. Consumers are looking to continue buying habits despite lower income and merchants are vying for ways to boost consumer spending. So when it comes to one of the biggest online merchants launching a buy-now-pay-later offering, its a big deal. It is, anyway for Read more...
- 08/04/2020
|
Worried about paying your bills? Here's who would qualify for a second $1,200 stimulus check
- CNBC Select takes a look at who would receive a second stimulus check proposed by both the House and the Senate amid the coronavirus pandemic.
- 08/04/2020
|
PayPal Stock Is on a Roll. Why Analysts Are Upbeat.
- PayPal doesn’t get as much attention as the tech behemoths, but it has outperformed four of the largest over the past three months.
- 08/04/2020
|
Embracing a mobile culture: How to satisfy customers without compromising security
- Digital technology is completely revolutionizing banking interactions.
- 08/04/2020
|
Diageo PLC (DEO) CEO Ivan Menezes on Q4 2020 Results - Earnings Call Transcript
- Diageo PLC (NYSE:DEO) Q4 2020 Earnings Conference Call August 04, 2020, 04:30 ET Company Participants Ivan Menezes - CEO & Executive Director Kathryn Mikells - CFO & Executive Director Conference Call Participants Sanjeet Aujla - Crédit Suisse Simon Hales - Citi Olivier Nicolai - Goldman Sachs Group Trevor Stirling - Sanford C.
- 08/04/2020
|
Citius Submits Mino-Wrap Briefing Package to FDA for Pre-IND Consult
- Citius Pharmaceuticals, Inc. ("Citius") ("Company") (NASDAQ: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products announced progress in the development of Mino-Wrap, a novel approach to reducing post-operative infections associated with surgical implants.
- 08/04/2020
|
Is The New JetBlue Cash + Points Option A Good Deal?
- JetBlue has grown in popularity since its founding in 1999, and even more as the airline has expanded its route map outside of the United States. The airline flies to numerous domestic destinations, but also to South America, Central America and the Caribbean. News also swirled last year that JetBlu
- 08/04/2020
|
Infineon Technologies : Shares Rise on Better-Than-Expected 3Q Results | MarketScreener
|
Australia central bank sees bumpy road to recovery as virus shuts down Victoria
- Australia central bank sees bumpy road to recovery as virus shuts down Victoria
- 08/04/2020
|
Minerva Neurosciences (NERV) Q2 2020 Earnings Call Transcript | The Motley Fool
- NERV earnings call for the period ending June 30, 2020.
- 08/03/2020
|
BNY Mellon, Citi, Visa, Others Invest $35 Million in Volante Technologies to Accelerate Fintech Firm's Cloud Expansion Globally
- BNY Mellon, Citi, Visa, others invest $35 Million in Volante Technologies to accelerate Fintech firm's cloud expansion globally.
- 08/03/2020
|
Citi Changes Its TTS Management Team | PYMNTS.com
- Citi has named Stephen Randall as the TTS global head of liquidity management services in the London office.
- 08/03/2020
|
Credit card issuers continue to offer financial assistance programs during coronavirus—here's what you need to know
- In March, major credit card issuers began offering support, including flexible bill payments and waived late fees, in response to the coronavirus pandemic — some continue to do so.
- 08/03/2020
|
Volante Technologies Receives $35M of Growth Funding from Leading International Investors to Accelerate Cloud Expansion Globally | PaymentsJournal
- Volante Technologies Inc., a leading provider of payments and financial messaging solutions in the cloud, today announced that it has raised USD 35M in growth equity financing led by Wavecrest Growth Partners with strategic participation from BNY Mellon, Citi Ventures, PostePay and Visa Inc. The capital raise represents the company’s first outside investment after nearly two decades of […]
- 08/03/2020
|
Citi BNPL Option Now On Amazon | PYMNTS.com
- Citi credit card holders can now use the company's Flex Pay option to buy products on Amazon.
- 08/03/2020
|
Microsoft Stock Spikes on TikTok Deal Talks. Why Fastly and SoftBank Are Also Up.
- President Donald Trump threatened to ban the popular app from the U.S. on security concerns, but that spurred discussions among ByteDance, Microsoft, and the Trump Administration about a potential transaction. Fastly and SoftBank have stakes in a potential deal, as well.
- 08/03/2020
|
Sale of Speedway gas stations buys Marathon breathing room
- The $21 billion sale of Speedway gas stations has bought Marathon Petroleum some breathing room as the global pandemic continues to punish the energy sector
- 08/03/2020
|
Gilead Stock Is Rising Because Covid-Treatment Sales Could Top $3 Billion
- Sales of its Covid-19 treatment could be worth more than $3 billion this year for Gilead Sciences, Citigroup’s Mohit Bansal says.
- 08/03/2020
|
HSBC slumps, capping rough first-half reporting season for U.K.-listed banks
- HSBC Holdings was a drag on the FTSE 100 on Monday, as the banking giant issued cautious guidance alongside a predictably dire first-half financial report.
- 08/03/2020
|
Citi Appointed Sole US Custodian by Peru’s Central Securities Depository CAVALI for Dual-Listed Securities
- Citi has been selected to provide custody and tax services by CAVALI S.A. ICLV S.A., the central securities depository (CSD) for the Lima Stock Exchan
- 08/03/2020
|
Siltronic AG (SSLLF) CEO Christoph von Plotho on Q2 2020 Results - Earnings Call Transcript
- Siltronic AG (OTCPK:SSLLF) Q2 2020 Results Conference Call July 30, 2020 04:00 AM ET Company Participants Petra Müller - IR Christoph von Plotho - CEO Rainer Irle - CFO Conference Call Participants Francois-Xavier Bouvignies - UBS Amit Harchandani - Citigroup Florian Treisch - Commerzbank Achal Sultania - Credit Suisse Jürgen Wagner - MainFirst Bank Robert Sanders - Deutsche Bank Veysel Taze - Bankhaus Lampe Presentation Petra Müller Thank you, operator.
- 08/02/2020
|
Top brokers name 3 ASX shares to sell next week
- Top brokers have named Fortescue Metals Group Limited (ASX:FMG) and these ASX shares as sells for next week. Here's why they are bearish...
- 08/01/2020
|
We're about to find out the biggest corporate winners and losers from COVID-19
- There hasn't been a corporate reporting season remotely like this — one that coincides with a pandemic, recession and record stimulus to keep entire industries from collapsing.
- 08/01/2020
|
U.S. IPO Weekly Recap: Vital Farms Pops 59% In A 7 IPO Week
- Seven IPOs and five SPACs entered the public markets this week. Vital Farms popped 59% in its public debut.
- 08/01/2020
|
Apple stock rockets to record as ‘amazingly strong’ earnings calm pandemic iPhone fears
- As Apple Inc. heads for the highly anticipated launch of its first 5G-enabled phone later this year, the company just gave a confident signal that its...
- 07/31/2020
|
Citi rend publique une nouvelle stratégie quinquennale en matière de développement durable
- Un objectif de financement environnemental de 250 milliards USD. L’analyse du risque climatique devrait s’approfondir. Citi sera alimentée à 100 % en électricité renouvelable au plus tard à la fin …
- 07/31/2020
|
I opened my first credit card 5 years ago—here are the top 5 rules I live by to responsibly manage my finances
- I opened my first credit card 5 years ago and since then I've added 9 more cards. Here are 5 rules I follow to responsibly manage my finances.
- 07/31/2020
|
Exxon’s debt load is expected to rise as it commits to paying dividend
- Exxon Mobil Corp. and Chevron Corp. report worse-than-feared second-quarter results on Friday, with Exxon’s commitment to preserving its dividend raising a...
- 07/31/2020
|
Zendesk Inc (ZEN) Q2 2020 Earnings Call Transcript | The Motley Fool
- ZEN earnings call for the period ending June 30, 2020.
- 07/31/2020
|
Stock market live Friday: Nasdaq jumps 1.5%, Gold tops $2,000 for first time, Apple record high
- Stocks ended July on a high note as Big Tech fueled gains for the major averages.
- 07/31/2020
|
Spain’s the Real Sore Spot as Europe’s Terrible Second-Quarter GDP Numbers Are Released
- The performance of Europe’s economies was awful all around in the second quarter, but one country really struggled: Spain.
- 07/31/2020
|
Future shape of offices: proposals to make workplaces safe
- Antimicrobial paint and rounded corners among plans to beat threat of coronavirus
- 07/31/2020
|
Shopify Posted Blowout Earnings. Here’s What Wall Street Is Saying.
- Almost every analyst who covers Shopify raised their target on the stock the day after the company’s earnings report.
- 07/30/2020
|
Budweiser’s Glass Is Unexpectedly Half-Full
- AB InBev had a better-than-expected second quarter as consumers in the U.S., China and Brazil kept drinking through the pandemic.
- 07/30/2020
|
Boeing’s ‘messy’ Q2 results get a pass from Wall Street
- Focus shifts to a better-than-expected free cash flow picture at Boeing Co., looking past wider losses and lower sales.
- 07/30/2020
|
Here are Thursday's biggest analyst calls of the day: Target, L Brands, Shopify, Amazon & more
- Here are the biggest calls on Wall Street on Thursday
- 07/30/2020
|
Citi to disclose loan portfolio CO2 as it pledges $250bn green spending blitz
- Bank to report and disclose the emissions tied to its lending portfolios as it joins Partnership for Carbon Accounting Financials (PCAF)
- 07/30/2020
|
Hot stocks: DBS, OCBC, UOB tumble after MAS asks to cap dividends
- SHARES of Singapore's local lenders extended their slide on Thursday morning, after the central bank asked them to cap dividend payouts. Read more at The Business Times.
- 07/30/2020
|
Citi, BofA to disclose how loans contribute to climate change
- The pair has joined Morgan Stanley among the roster of global banks pledging to measure the impact their lending decisions have on global warming. Citi also said it would finance $250 billion of low-carbon projects.
- 07/29/2020
|
How you answer this one question determines how you should invest right now
- The S&P 500 may end 2020 below where it is today, but do you think the U.S. economy will be in a better place in 18 months?
- 07/29/2020
|
USD: Can The USD Sell-Off Resume? A Look At Technicals, Positioning & Month-End Flows - Citi | Forex Crunch
- The US dollar has lost ground recently against the major currencies. What is the outlook for a further sell-off? Here is their view, courtesy of eFXdata:
- 07/29/2020
|
How the new Nasdaq-like tech board in Hong Kong will benefit investors and tech giants
- Hong Kong launched a new, Nasdaq-style tech board this week, tracking 30 of the largest tech stocks listed in the city.
- 07/29/2020
|
As Precious Metals Sizzle, Can Copper Break $3?
- Commodities Analysis by Investing.com (Barani Krishnan/Investing.com) covering: XAU/USD, XAG/USD, Gold Futures, Copper Futures. Read Investing.com (Barani Krishnan/Investing.com)'s latest article on Investing.com
- 07/29/2020
|
Future Returns: REITs Should Rise as Economy Recovers
- Citi Private Bank expects the sector to benefit over the next 12-to-18 months, driven also by long-term trends
- 07/28/2020
|
Hong Kong's new tech index up 3.5% on the second day of trade
- The tech index was launched on Monday and tracks the 30 largest technology companies listed in Hong Kong that pass the screening criteria.
- 07/28/2020
|
USD: Expecting Muted Market Reaction From This Week's FOMC - Citi | Forex Crunch
- The Federal Reserve holds its monthly policy meeting later on Wednesday. What can the markets expect from the FOMC? Here is their view, courtesy of
- 07/28/2020
|
Top broker warns earnings expectations for the ASX reporting season are too high
- If you are feeling nervous about the ASX reporting season, you should be as Citigroup is warning that expectations may be set too high.
- 07/28/2020
|
Weekly Ratings, Targets, Forecast Changes - 24-07-20 - FNArena
- Weekly update on stockbroker recommendation, target price, and earnings forecast changes
- 07/27/2020
|
Citius Pharmaceuticals Forms Scientific Advisory Board for the Planned Development of its Proprietary Treatment for Acute Respiratory Disease Associated with COVID-19
- Citius Pharmaceuticals, Inc. ("CITIUS") ("Company") (NASDAQ: CTXR), a specialty pharmaceutical company focused on developing and commercializing critical care drug products, announced today the formation of the Citius ARDS (Acute Respiratory Distress Syndrome) Scientific Advisory Board to provide the company expert guidance on its planned development of induced mesenchymal stem cells (iMSCs) under option from Novellus, Inc. to treat and reduce the severity of acute respiratory distress syndrome (ARDS) associated with COVID -19.
- 07/22/2020
|
Citius Pharmaceuticals to Present at the MoneyShow Accredited Investor Virtual Event
- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company focused on developing and commercializing critical care drug products, announced today that the company will deliver a presentation at the MoneyShow Accredited Investor Virtual Event that is being held July 22 – 24, 2020.
- 07/20/2020
|
Citius Pharmaceuticals (NASDAQ:CTXR) Shares Gap Up to $1.35
- Citius Pharmaceuticals Inc (NASDAQ:CTXR)’s stock price gapped up prior to trading on Friday . The stock had previously closed at $1.52, but opened at $1.35. Citius Pharmaceuticals shares last traded at $1.40, with a volume of 17,631 shares trading hands. CTXR has been the topic of a number of analyst reports. HC Wainwright reissued a […]
- 07/19/2020
|
Citius Pharmaceuticals Brings on Myron S. Czuczman, M.D. as Chief Medical Officer (CMO) and Executive Vice President
- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company focused on developing and commercializing critical care drug products, announced today that Myron S. Czuczman, M.D., has joined the company as Chief Medical Officer (CMO) and Executive Vice President. Dr. Czuczman was most recently Therapeutic Area Head, Vice President, Clinical Research and Development Global Lymphoma/CLL Program at Celgene Corporation. At Celgene, he was responsible for worldwide clinical development in Lymphoma/CLL and for the development of all compounds from Proof-of-Principle through registration globally.
- 07/14/2020
|
Citius Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements
|
Citius Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements
- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (NASDAQ: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, announced that it received notice from The Nasdaq Stock Market LLC ("NASDAQ") on July10, 2020 indicating that the Company has regained compliance with the minimum bid price requirement under NASDAQ Listing Rule 5550(a)(2) (the "Bid Price Rule") for continued listing on The NASDAQ Capital Market. Accordingly, the Company has regained compliance with the Bid Price Rule and NASDAQ considers the matter closed.
- 07/13/2020
|
H.C. Wainwright Thinks Neovasc's Stock is Going to Recover - Markets
- H.C. Wainwright analyst Vernon Bernardino reiterated a Buy rating on Neovasc (NVCN – Research Report) today and set a price
- 07/02/2020
|
Citius Pharmaceuticals (CTXR) Jumps: Stock Rises 5.1%
- Citius Pharmaceuticals (CTXR) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
- 06/30/2020
|
Citius CEO Myron Holubiak to Appear on TD Ameritrade Network's The Watch List with Nicole Petallides
- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company focused on developing and commercializing critical care drug products, announced today that its CEO, Myron Holubiak, is scheduled to appear as a featured guest on TD Ameritrade Network's The Watch List with host Nicole Petallides on Tuesday, June 30, 2020 at 1:20pm ET. Interested parties may view the live interview at https://tdameritradenetwork.com/.
- 06/29/2020
|
Life Sciences Companies Investor Presentations Now Available for On-Demand Viewing
- NEW YORK, June 29, 2020 -- Life Sciences Investor Forum today announced that the presentations from the June 25th conference are now available for on-demand viewing at.
- 06/29/2020
|
Cel-Sci (CVM) Receives a Buy from H.C. Wainwright - Markets
- In a report released today, Vernon Bernardino from H.C. Wainwright reiterated a Buy rating on Cel-Sci (CVM – Research Report),
- 06/29/2020
|
Analysts Offer Insights on Healthcare Companies: Novan (NASDAQ: NOVN), Novavax (NASDAQ: NVAX) and Arena Pharma (NASDAQ: ARNA) - Markets
- There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Novan (NOVN
- 06/29/2020
|
Citius Pharmaceuticals : CTXR Presentation - Summer 2020 | MarketScreener
|
Citius Pharmaceuticals (CTXR) Investor Presentation - Slideshow
- The following slide deck was published by Citius Pharmaceuticals, Inc. in conjunction with this event.
- 06/26/2020
|
Citius Receives FDA Response on Pre-Investigational New Drug (PIND) Application for its Induced Mesenchymal Stem Cells (iMSCs) to Treat Acute Respiratory Distress Syndrome (ARDS) in Patients with COVID-19
- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company focused on developing and commercializing critical care drug products, announced today that the Company has received a written response from the U.S. Food and Drug Administration (FDA) in regards to its pre-investigational new drug (PIND) application for its induced mesenchymal stem cells (iMSCs) to treat and reduce the severity of acute respiratory distress syndrome (ARDS) in patients with COVID-19.
- 06/26/2020
|
Citius Pharmaceuticals (NASDAQ:CTXR) Rating Lowered to Sell at Zacks Investment Research
- Citius Pharmaceuticals (NASDAQ:CTXR) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report released on Monday, Zacks.com reports. According to Zacks, “Citius Pharmaceuticals, Inc. is a specialty pharmaceutical company. It engaged in the development and commercialization of critical care products targeting medical needs with a focus on anti-infective […]
- 06/24/2020
|
Virtual Conference for Life Sciences Companies Broadcast Live June 25, 2020
- NEW YORK, June 23, 2020 -- Life Sciences Investor Forum today announced the agenda for its second quarterly event for public and private companies, investors and industry.
- 06/23/2020
|
Citius Pharmaceuticals to Deliver Virtual Presentation at the Life Sciences Investor Forum
- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company focused on developing and commercializing critical care drug products, announced today that Chief Executive Officer Myron Holubiak will deliver a virtual presentation at the Life Sciences Investor Forum on Thursday, June 25, 2020 at 11:00 AM ET.
- 06/22/2020
|
Global Microbiology Analyzers Market Assessment and Forecast 2015-2025 - COVID-19 Updated - ResearchAndMarkets.com
|
Citius Receives Positive FDA Feedback on Its Submitted Plan to Study Catheter Compatibility for Mino-Lok® Therapy
- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company focused on developing and commercializing critical care drug products, today announced that it has received positive feedback from the Food and Drug Administration (FDA) on its proposed catheter compatibility studies for the Company's Mino-Lok® therapy. The studies, if and when successfully completed, should allow Mino-Lok to be labeled for use with all commercially available central venous catheters (CVCs) and peripherally inserted central catheters (PICCs) on the U.S. market. It is further assumed that these studies will meet European and world standards.
- 06/02/2020
|
Citius Announces Expanded Access Program for Investigational Phase 3 Mino-Lok®
- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company focused on developing and commercializing critical care drug products, today announced that it is providing free access to Mino-Lok® for healthcare providers under an Expanded Access protocol to ease the burden associated with the COVID-19 pandemic.
- 05/26/2020
|
Citius Announces Closing of $7.5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
- Citius Pharmaceuticals Inc. (Nasdaq: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, today announced the closing of the previously announced registered direct offering priced at-the-market under Nasdaq rules. In the offering, Citius sold 7,058,824 shares of its common stock, at a purchase price per share of $1.0625. Additionally, Citius issued to the investors unregistered warrants to purchase up to 3,529,412 shares of its common stock.
- 05/18/2020
|
Should You Be Concerned About Citius Pharmaceuticals, Inc.'s (NASDAQ:CTXR) Historical Volatility?
- Anyone researching Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) might want to consider the historical volatility of the...
- 05/15/2020
|
Citius Announces $7.5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
- Citius Pharmaceuticals, Inc. (Nasdaq: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, today announced that it has entered into definitive agreements with several institutional and accredited investors for the purchase of 7,058,824 shares of its common stock, at a purchase price per share of $1.0625 for gross proceeds of approximately $7.5 million, in a registered direct offering priced at-the-market under Nasdaq rules. Additionally, Citius has also agreed to issue to the investors unregistered warrants to purchase up to 3,529,412 shares of its common stock. The closing of the offering is expected to take place on or about May 18, 2020, subject to the satisfaction of customary closing conditions.
- 05/14/2020
|
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 1.62%
- U.S. stocks higher at close of trade; Dow Jones Industrial Average up 1.62%
- 05/14/2020
|
Citius Announces Data on NoveCite Mesenchymal Stem Cells (NC-MSCs) to be Presented at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company focused on developing and commercializing critical care drug products, today announced that data on NoveCite MSCs will be presented this week at the American Society of Gene and Cell therapy (ASGCT) annual meeting. NC-MSCs are made by Novellus, Inc. ("Novellus"), a Cambridge-based biotechnology company, using its patented mRNA-based cell-reprogramming process. Earlier this year, Citius signed an exclusive option agreement to in-license NC-MSCs for acute respiratory distress syndrome (ARDS), including in COVID-19 patients, from Novellus.
- 05/13/2020
|
Citius Pharmaceuticals Issues May 2020 Shareholder Letter
- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company focused on developing and commercializing critical care drug products, today announced that the Company has issued its May 2020 Shareholder Letter. The letter highlights the Company's exclusive option to license a novel stem-cell therapy to treat acute respiratory distress syndrome (ARDS) associated with COVID-19, and the clinical progress of the Company's core products: Mino-Lok®, Mino-Wrap™, and Halo-Lido.
- 05/12/2020
|
Digital Investor Communications Platform Proxymity Raises $20.5 Million Through Strategic Investment Round & Forms Global Consortium
- Click HERE to find out ⭐ Digital Investor Communications Platform Proxymity Raises $20.5 Million Through Strategic Investment Round & Forms Global Consortium. | Crowdfund Insider: Global Fintech News, including Crowdfunding, Blockchain and more.
- 05/05/2020
|
FDA Expediting Accelerated Development of Novel Therapies for COVID-19
- The U.S. Federal government is working closely with companies and researchers to find treatments and vaccines to overcome the global health crisis. The FDA has been cutting red tape and has launched new programs that relax certain time consuming regulations while still assuring the efficacy and safety
- 04/28/2020
|
Citius Announces Pre-IND Submission to FDA Under the Coronavirus Treatment Acceleration Program for a Novel Stem Cell Therapy for Acute Respiratory Distress Syndrome (ARDS) in COVID-19
- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company focused on developing and commercializing critical care drug products, today announced that it submitted a pre-IND meeting request and supporting briefing documents to the Center for Biologics Evaluation and Research ("CBER") of the FDA under the Coronavirus Treatment Acceleration Program (CTAP) on April 24. The Company has requested the Division's feedback to support the most expeditious pathway into the clinic to evaluate a novel cell therapy in patients suffering from COVID-19-related ARDS.
- 04/27/2020
|
Citius Signs Exclusive Option with Novellus to License Novel Stem-Cell Therapy for Acute Respiratory Distress Syndrome (ARDS) Associated with COVID-19
- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company focused on developing and commercializing critical care drug products, today signed an exclusive six-month option agreement to in-license a stem-cell therapy for acute respiratory distress syndrome (ARDS) from a subsidiary of Novellus, Inc., a preclinical-stage biotechnology company based in Cambridge, MA.
- 04/01/2020
|
Citius Pharmaceuticals Announces Publication in Antimicrobial Agents and Chemotherapy Journal of Positive Preclinical Results for Mino-Lok® in Rapidly Eradicating Candida Auris
- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, announced today the publication of an in vitro study for Mino-Lok®, the Company's antibiotic lock solution used to treat patients with central line associated blood stream infections (CLABSIs) and catheter-related bloodstream infections (CRBSIs), in the March 2020 issue of Antimicrobial Agents and Chemotherapy. The article, titled "Minocycline-EDTA-Ethanol Antimicrobial Catheter Lock Solution Is Highly Effective In Vitro for Eradication of Candida auris Biofilms," highlights the in vitro efficacy of Mino-Lok against various strains of Candida auris ("C. auris") from studies conducted at MD Anderson Cancer Center Labs.
- 03/26/2020
|
Citius Pharmaceuticals to Deliver Virtual Presentation at the Spring Investor Summit
- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, announced today that Chief Executive Officer Myron Holubiak will deliver a virtual presentation at the Spring Investor Summit on Wednesday, March 25, 2020 at 8:50 AM ET.
- 03/18/2020
|
Here's Why We Worry About Citius Pharmaceuticals's (NASDAQ:CTXR) Cash Burn Situation
- There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
- 03/16/2020
|
Citius Pharmaceuticals, Inc. to Present at the Spring Investor Summit on March 25th-26th in New York City
- NEW YORK, NY / ACCESSWIRE / March 3, 2020 / Citius Pharmaceuticals, Inc. (NASDAQ:CTXR), is a specialty pharmaceutical company dedicated to the development and commercialization of drug products that address ...
- 03/03/2020
|
Alternative real estate assets: get ready for the floats
- The local stock exchange is beckoning ever more strongly for a growing range of REITs focused on alternative asset classes.
- 02/26/2020
|
Citius Pharmaceuticals to Present at the 2020 LD Micro Virtual Conference
- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, announced today that the Company will present at the Third Annual LD Micro Virtual Conference on Wednesday, March 4, 2020 at 11 AM ET.
- 02/26/2020
|
Citius Pharmaceuticals Cites Independent Estimates of Total Available World Market for Mino-Lok®
- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, today cited independent research on the incidence of catheter-related blood stream infections (CRBSIs) in the world.
- 02/25/2020
|
Citius Pharmaceuticals to Present at Noble Capital Markets' 16th Annual Investor Conference
- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (NASDAQ: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, announced today that the Company will present at Noble Capital Markets' 16th Annual Investor Conference on Monday, February 17, 2020 at 4:00 PM ET. The conference is being held at the Seminole Hard Rock Hotel & Casino in Hollywood, Florida on February 16-18, 2020.
- 02/10/2020
|
ASX snaps three-day losing streak: Aus shares 0.1% higher at noon
- 24 Oct 2018 - Market at Midday. ASX claws back from earlier fall. Citi issues alert for Healthscope (ASX:HSO) saying new takeover offer is a 32% premium. Brambles (ASX:BXB) and Centuria Metro. REIT (ASX:CMA) upgraded. Iluka (ASX:ILU) revenue & sales rise. WorleyParsons (ASX:WOR) raises $1.8b. PINCHme.com (ASX:PIN) starts trading.
- 02/10/2020
|
Citius Achieves 50% Patient Enrollment in Phase 3 Mino-Lok® Pivotal Trial
- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (NASDAQ: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical-care drug products, today announced that the Company's lead program, Mino-Lok vs. standard-of-care ("SOC") antibiotic locks, has randomized its 72nd patient, thereby passing the halfway point for enrollment in this Phase 3 trial. The Company previously announced the results of a futility analysis when it passed the threshold of 40% of patients completing end of therapy. That analysis showed a positive outcome, as it met the prespecified interim futility analysis criteria. The next major milestone in the Mino-Lok trial, expected to be achieved in the first half of 2020, will be the 75% interim analysis for superior efficacy. The endpoints for this analysis require that the time to catheter failure be at least 38 days for Mino-Lok vs. 21 days for SOC antibiotic locks.
- 02/04/2020
|
Citi Bank Backs Cobalt’s Forex Post-Trade Infrastructure | Finance Magnates
- Cobalt, the FX post-trade infrastructure, has announced this Tuesday that Citi bank is the latest market player to support its infrastructure.
- 02/04/2020
|
Citius Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements
- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (NASDAQ: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, announced that it received notice from The Nasdaq Stock Market LLC ("NASDAQ") on January 31, 2020 indicating that the Company has regained compliance with the minimum bid price requirement under NASDAQ Listing Rule 5550(a)(2) (the "Bid Price Rule") for continued listing on The NASDAQ Capital Market. Accordingly, the Company has regained compliance with the Bid Price Rule and NASDAQ considers the matter closed.
- 02/03/2020
|
Biotech Companies Think Big with Specialization - Fighting Deadly Bacteria and Viruses
- Point Roberts, Washington and Vancouver, British Columbia--(Newsfile Corp. - January 27, 2020) - Investorideas.com, a leading investor news resource covering pharmaceutical and biotechnology stocks releases a special report on the opportunity within the specialty drug segment of the sector to address viral outbreaks and bacterial resistance, featuring Citius Pharmaceuticals, Inc. (NASDAQ: CTXR). Read the full article on Investorideas.comhttps://www.investorideas.com/News/2020/biotech/01270Specialization-FightingBacteriaViruses.aspCertain social and technological advancements as well as new and deadlier viral (coronavirus) and bacterial outbreaks are ...
- 01/27/2020
|
YieldStreet Announces New Partnership With Citi For Access to Private Credit Opportunities Delivery
- Click HERE to find out ⭐ YieldStreet Announces New Partnership With Citi For Access to Private Credit Opportunities Delivery. | Crowdfund Insider: Global Fintech News, including Crowdfunding, Blockchain and more.
- 01/08/2020
|
Citius Announces Positive Outcome of Interim Futility Analysis for its Phase 3 Mino-Lok® Pivotal Trial
- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (NASDAQ: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, today announced a positive outcome of the pre-specified interim futility analysis for the Phase 3 clinical trial of Mino-Lok® vs. standard-of-care antibiotic locks. The analysis was conducted by the Mino-Lok trial Data Monitoring Committee ("DMC"), an independent panel of experts charged with periodically monitoring the safety and efficacy of the progress of the pivotal trial. The Company reached and completed the prespecified 40% enrollment required for the interim futility analysis in late September and, based on the analysis of the data and recommendations of the DMC, will proceed with the current trial as planned. Topline data from the superior efficacy interim analysis, the next major milestone in the Mino-Lok trial, is expected in the first half of 2020. The market potential for an effective antibiotic lock therapy is estimated at $750 million per year in the U.S. and approximately $1.5 billion per year worldwide.
- 12/19/2019
|
Citius Pharmaceuticals to Present at the 12th Annual LD Micro Main Event
- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (NASDAQ: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, announced today that the Company will present at the 12th Annual LD Micro Main Event on Wednesday December 11, 2019 at 11:40 AM PT. The conference is being held at the Luxe Sunset Boulevard Hotel in Bel Air, California on December 10-12, 2019.
- 12/04/2019
|
New Google Checking Accounts Threaten to Shake Up Banking Industry
- If banks and credit unions don't partner with Google 'Cache' to extend banking services, do they risk becoming digitally irrelevant?
- 11/19/2019
|
Citi’s Treasury and Trade Solutions Releases New Supplier Finance Offering for Transacting in Major Currencies for Settlement
- Citi’s Treasury and Trade Solutions introduces new supplier finance offering for transacting in major currencies for settlement.
- 10/22/2019
|
Citi Teams Up with Software Fintech Cachematrix to Launch Refreshed Digital Investment Portal
- Click HERE to find out ⭐ Citi Teams Up with Software Fintech Cachematrix to Launch Refreshed Digital Investment Portal. | Crowdfund Insider: Global Fintech News, including Crowdfunding, Blockchain and more.
- 10/08/2019
|
Citi Hong Kong Announces New Digital Payment Solution That Enables Credit Cardholders to Settle Big Ticket Payments on Citi Mobile App
- Click HERE to find out ⭐ Citi Hong Kong Announces New Digital Payment Solution That Enables Credit Cardholders to Settle Big Ticket Payments on Citi Mobile App. | Crowdfund Insider: Global Fintech News, including Crowdfunding, Blockchain and more.
- 08/05/2019
|
Wells Fargo speculation, female-friendly fintechs and Most Powerful Women on the move
- Is it realistic to think Wells Fargo might get a new female CEO? How one fintech makes women feel welcome, and how another fosters innovation. Two of the Most Powerful Women in Banking retire and a third jumps to Amex.
- 03/06/2019
|
Say Watt? Former FHFA head gets sniffy about his misconduct, and proxy pressure builds
- Mel Watt calls FHFA watchdog “sexist,” after it concludes he’s guilty of sexual harassment. State Street sues the "Fearless Girl" sculptor. Banks big and small face mounting pressure on gender pay gap and board diversity. And another top 40 U.S. bank might get a female CEO.
- 02/21/2019
|
Citi expects privatization to bolster revenue in Brazil | MarketScreener
|
"Mind The Gap!" The life and times of a man on the move. Episode 3 - FinanceFeeds
- Cornwall is London-On-Sea, Amsterdam airport burgers up a good opportunity, a buffoon with a balloon, the wastefulness of arrogance, poking your best friend in the eye and are friends electric?
- 07/15/2018
|
Les robots pourraient remplacer jusqu'à 10.000 employés chez Citi
- Les robots pourraient remplacer jusqu'à 10.000 emplois humains chez Citi, le géant américain du secteur bancaire, d'ici cinq...
- 06/12/2018
|
Citibank Checking Account Review: Customer Satisfaction and Savings
- Find out what a Citibank checking account has to offer.
- 02/04/2018
|
US Bankers invited to Saudi Arabia to pitch for Aramco listing roles
- LONDON/DUBAI (Reuters) – Saudi Aramco has invited banks pitching for roles in its stock market listing, including Citi and Goldman Sachs, for meetings in the kingdom in the coming weeks to ma…
- 01/08/2018
|
Bullish Citi analysts see crude oil hit $70 by year end but elsewhere skepticism grows
- Crude oil prices could shoot up to $70 a barrel by the end of 2017 as supply and demand levels continue to rebalance in coming months, according to analysts at Citi. Nearer-term, the research team …
- 02/22/2017
|
Print Article
- Visit the post for more.
- 08/14/2014
|
